Hanall Biopharma Co.,Ltd (009420.KS)

KRW 27350.0

(2.82%)

Market Cap (In KRW)

1388.43 Billion

Revenue (In KRW)

134.9 Billion

Net Income (In KRW)

3.5 Billion

Avg. Volume

498.74 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
28500.0-52000.0
PE
-
EPS
-
Beta Value
0.748
ISIN
KR7009420001
CUSIP
-
CIK
-
Shares
50765573.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Sean Jeong
Employee Count
-
Website
https://www.hanall.co.kr
Ipo Date
2000-01-04
Details
Hanall Biopharma Co.,Ltd, a pharmaceutical company, researches, develops, and sells pharmaceutical products in South Korea and internationally. The company offers specialty drugs and over-the-counter products for the treatment of gastric and duodenal ulcers, gastritis, cerebrovascular and peripheral blood vessel disorder, hypertension, atherosclerotic symptom, acute coronary syndrome, atherothrombosis and thromboembolism, diabetes, osteoporosis, chronic kidney failure, hypothyroidism, vitamin D-resistant rickets, osteomalacia, erectile dysfunction, prostatic hyperplasia, candidiasis, various fungal infections, prostate cancer, formal, constipation, thin stools, bloating, bowel abnormal fermentation, and hemorrhoids. The company was founded in 1973 and is based in Seoul, South Korea.